ArticleJournal of the American Heart Association2025
Clinical Impact of Early Changes in Serum Albumin on Patient Prognosis After Mitral-Transcatheter Edge-to-Edge Repair.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLow serum albumin levels indicate frailty and are strong predictors of poor prognosis after mitral transcatheter edge-to-edge repair (M-TEER); however, albumin levels are expected to improve in response to treatment for mitral regurgitation. No reports have elucidated the clinical effects of albumin changes after M-TEER. Thus, we aimed to explore the association between early albumin changes and clinical outcomes after M-TEER and to identify the associated factors.
methodsData from 2695 patients enrolled in a Japanese multicenter registry whose serum albumin levels were measured before and 1 month after undergoing M-TEER were retrospectively reviewed. Changes in albumin (Δ-albumin) were calculated and divided into 2 groups, namely improved albumin (Δ-albumin >0) and worsening albumin (Δ-albumin ≤0) groups. The incidence, predictors, and clinical outcomes associated with early albumin changes were investigated.
resultsAfter M-TEER, albumin levels improved in 56.1% of the patients (n=1512). The independent predictors of worsening Δ-albumin comprised old age, acute procedure success not achieved, higher Clinical Frailty Scale, higher hemoglobin, impaired renal function, and preprocedural higher albumin levels (all
conclusionsEarly improvement in Δ-albumin may serve as a measure of procedural benefits and a surrogate marker for predicting clinical outcomes after M-TEER.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.